Infliximab
Treatment for Crohn's Disease
Typical Dosage: 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Effectiveness
75%
Safety Score
40%
Clinical Trials
176
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$1,150
Side Effect Mgmt:$750
Total Annual:$11,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$55,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$18,308
Cost per Remission
$29,750
Infliximab Outcomes
for Crohn's Disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Remission Rate
+40%
Common Side Effects
Infusion reactions
+15%
Upper respiratory tract infection
+25%
Headache
+15%
Serious infections
+4%
Malignancy (lymphoma, skin cancer)
+0.5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
5 active trials recruiting for Infliximab in Crohn's Disease
Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
NCT07415473NOT YET RECRUITINGPHASE4
400 participants
INTERVENTIONAL
Started: Apr 1, 2026
Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
NCT07417696NOT YET RECRUITINGPHASE4
400 participants
INTERVENTIONAL
Started: Apr 1, 2026
Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
NCT06064864RECRUITINGNA
100 participants
INTERVENTIONAL
Seoul, South Korea
Started: Oct 9, 2023
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
NCT07424040NOT YET RECRUITINGNA
154 participants
INTERVENTIONAL
Kunming, China +3 more
Started: Mar 1, 2026
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
NCT05906576RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Beijing, China
Started: Sep 21, 2023
Completed Clinical Trials
11 completed trials for Infliximab in Crohn's Disease
Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease
NCT01442025COMPLETEDPHASE4
121 participants
INTERVENTIONAL
Amiens, France +11 more
Started: Jun 1, 2012
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
NCT00705614COMPLETED
2.66K participants
OBSERVATIONAL
Started: Jul 1, 2003
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
NCT00988832COMPLETED
380 participants
OBSERVATIONAL
Started: Feb 1, 2010
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
NCT02096861COMPLETEDPHASE3
220 participants
INTERVENTIONAL
Nashville, United States
Started: Sep 19, 2014
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
NCT00818272COMPLETED
148 participants
OBSERVATIONAL
Started: Dec 1, 2002
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
NCT00004941COMPLETEDPHASE3
94 participants
INTERVENTIONAL
Started: Jul 1, 1996
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
NCT00724958COMPLETED
348 participants
OBSERVATIONAL
Started: Dec 1, 2004
Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
NCT01661257COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Seoul, South Korea
Started: Oct 1, 2009
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
NCT03884439COMPLETED
428 participants
OBSERVATIONAL
Tokyo, Japan
Started: Mar 18, 2019
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
NCT03890445COMPLETED
63 participants
OBSERVATIONAL
Innsbruck, Austria +17 more
Started: Jun 24, 2019
Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
NCT04272788COMPLETED
32 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 24, 2017
Showing 20 of 188 total trials